3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
14
Endometrial Neoplasms
11
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Rectal Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Osteosarcoma
2
Locally Advanced Rectal Cancer (LARC)
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
fludarabine
2
Paclitaxel
2
Gemcitabine
2
Bevacizumab
2
pembrolizumab
1
liposomal doxorubicin
1
dostarlimab
1
Taxes
1
Stem Cell Transplantation
1
Sirolimus
1
Nivolumab
1
Melphalan
1
Ipilimumab
1
Immunoglobulin G
1
Doxorubicin
1
Docetaxel
1
Disulfides
1
Dexamethasone
1
Carboplatin
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
dostarlimab
×
1 year
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled